Literature DB >> 11150108

Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma.

T Anttila1, P Saikku, P Koskela, A Bloigu, J Dillner, I Ikäheimo, E Jellum, M Lehtinen, P Lenner, T Hakulinen, A Närvänen, E Pukkala, S Thoresen, L Youngman, J Paavonen.   

Abstract

CONTEXT: Human papillomavirus (HPV) infection has been established as a cause of cervical cancer. Epidemiologic studies suggest that Chlamydia trachomatis infection also confers increased risk for cervical squamous cell carcinoma (SCC). Whether this risk is serotype-specific is unknown.
OBJECTIVE: To study the association between exposure to different C trachomatis serotypes and subsequent development of cervical SCC. DESIGN AND
SETTING: Longitudinal, nested case-control study within a cohort of 530 000 women who provided samples to serum banks in Finland, Norway, and Sweden. The data files were linked to respective national cancer registries.
SUBJECTS: One hundred twenty-eight women who had developed invasive cervical SCC at least 12 months following serum donation. Each case had 3 matched controls. MAIN OUTCOME MEASURE: Risk for the development of cervical SCC by IgG antibodies to 10 different C trachomatis serotypes, adjusted for antibodies to HPV types 16, 18, and 33 and for serum cotinine levels.
RESULTS: Of specific C trachomatis serotypes, serotype G was most strongly associated with SCC (adjusted odds ratio [OR], 6.6; 95% confidence interval [CI], 1. 6-27.0). Other serotypes associated with SCC were I (OR, 3.8; 95% CI, 1.3-11.0) and D (OR, 2.7; 95% CI, 1.3-5.6). Presence of serum IgG antibodies to more than 1 serotype increased the adjusted ORs for SCC (P<.001 for trend).
CONCLUSIONS: Chlamydia trachomatis serotype G is most strongly associated with subsequent development of cervical SCC. Increasing numbers of exposures to different C trachomatis serotypes also increases risk. Our results strengthen the evidence that there is a link between past C trachomatis infection and cervical SCC.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11150108     DOI: 10.1001/jama.285.1.47

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  80 in total

Review 1.  Immunity to murine chlamydial genital infection.

Authors:  Richard P Morrison; Harlan D Caldwell
Journal:  Infect Immun       Date:  2002-06       Impact factor: 3.441

2.  Evaluation of the polyclonal ELISA HPV serology assay as a biomarker for human papillomavirus exposure.

Authors:  Sarah E Coseo; Carolina Porras; Lori E Dodd; Allan Hildesheim; Ana Cecilia Rodriguez; Mark Schiffman; Rolando Herrero; Sholom Wacholder; Paula Gonzalez; Mark E Sherman; Silvia Jimenez; Diane Solomon; Catherine Bougelet; Leen-Jan van Doorn; Wim Quint; Mahboobeh Safaeian
Journal:  Sex Transm Dis       Date:  2011-10       Impact factor: 2.830

3.  Concomitant Chlamydia trachomatis and human papilloma virus infection cannot be attributed solely to sexual behaviour.

Authors:  V Verhoeven; M Baay; J Weyler; D Avonts; F Lardon; P Van Royen; J B Vermorken
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-08-18       Impact factor: 3.267

4.  Chlamydial infection induces host cytokinesis failure at abscission.

Authors:  Heather M Brown; Andrea E Knowlton; Scott S Grieshaber
Journal:  Cell Microbiol       Date:  2012-06-19       Impact factor: 3.715

5.  Association of tubal factor infertility with elevated antibodies to Chlamydia trachomatis caseinolytic protease P.

Authors:  Allison K Rodgers; Jie Wang; Yingqian Zhang; Alan Holden; Blake Berryhill; Nicole M Budrys; Robert S Schenken; Guangming Zhong
Journal:  Am J Obstet Gynecol       Date:  2010-11       Impact factor: 8.661

6.  Lymphogranuloma venereum prevalence in Sweden among men who have sex with men and characterization of Chlamydia trachomatis ompA genotypes.

Authors:  Markus Klint; Margareta Löfdahl; Carolina Ek; Asa Airell; Torsten Berglund; Björn Herrmann
Journal:  J Clin Microbiol       Date:  2006-09-13       Impact factor: 5.948

7.  Development of secondary inclusions in cells infected by Chlamydia trachomatis.

Authors:  Robert J Suchland; Daniel D Rockey; Sara K Weeks; Damir T Alzhanov; Walter E Stamm
Journal:  Infect Immun       Date:  2005-07       Impact factor: 3.441

8.  Evolution of Chlamydia trachomatis diversity occurs by widespread interstrain recombination involving hotspots.

Authors:  João P Gomes; William J Bruno; Alexandra Nunes; Nicole Santos; Carlos Florindo; Maria J Borrego; Deborah Dean
Journal:  Genome Res       Date:  2006-11-07       Impact factor: 9.043

9.  Impact of Chlamydia trachomatis and HPV infection among sexually active teenage girls in Upper Silesia, Poland.

Authors:  Daniela Friedek; Alicja Ekiel; Malgorzata Romanik; Zbigniew Chelmicki; Artur Chelmicki; Gayane Martirosian
Journal:  J Korean Med Sci       Date:  2005-08       Impact factor: 2.153

Review 10.  Chlamydia trachomatis today: treatment, detection, immunogenetics and the need for a greater global understanding of chlamydial disease pathogenesis.

Authors:  D Dean
Journal:  Drugs Today (Barc)       Date:  2009-11       Impact factor: 2.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.